EXTENDED REPORT

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)


ABSTRACT

Objectives Treat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.

Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.

Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:
1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by ……………………. (reference to symptoms, signs, routine labs).
2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician’s global assessment.
3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics.

The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life.

Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.

INTRODUCTION

Outcomes in systemic lupus erythematosus (SLE) have improved considerably over the past decades. For the most widely studied specific organ involvement in SLE, lupus nephritis, results from clinical trial follow-up studies demonstrate that the long-term renal survival in this condition has now improved to >90%. However, not all outcomes in SLE show the same favourable trends. Most notably, the overall health-related quality of life (HR-QoL) for patients with SLE remains reduced. This and other considerations prompted the initiation of the treat-to-target for SLE (T2T/SLE), initiative which over the past several years established an international consensus on the approach to the therapy of SLE based on (1) identifying an appropriate target for each patient; (2) initiating treatment steps to try to achieve this target; (3) assessing the target and (4) adjusting the therapeutic approach, if necessary. These elaborations led to the T2T/SLE recommendations published in 2014. One of the most significant targets in SLE was identified as ‘remission of systemic symptoms.
and organ manifestations. However, it was recognised by the panel that no generally accepted definition of remission in SLE exists today. Such a definition could be important for basic, clinical and epidemiological studies and clinical trials in lupus, and also for clinical practice. The literature on this topic demonstrates that many clinical trials and observational studies have used a large number of different ad hoc definitions of remission; many of these were reviewed in a recent study. Consequently, the T2T/SLE panel identified the definition of remission as a research priority for SLE. In response, an initiative was undertaken in order to achieve consensus in a large multiparty international task force on potential definitions of remission in SLE (DORIS).

**METHODS**

An international task force consisting of rheumatologists, nephrologists, dermatologists, clinical immunologists and patient representatives, totalling 60 individuals, was convened. In March 2014, a preliminary meeting was held by a steering committee consisting of 15 of these representatives. The steering committee identified four domains critical to further development of remission definitions; 10 preliminary statements regarding remission that were felt to be uncontroversial; key controversies and a set of proposed topics for further discussion. During the following 4-month period, the 10 preliminary statements were presented to the full task force electronically, submitted upon by email and then subjected to formal electronic voting. High-level agreement was readily achieved for eight of these, whereas two were placed on the agenda for the subsequent consensus conference. Moreover, an additional number of key topics were identified during these deliberations that were to be dealt with more thoroughly at the face-to-face meeting.

In August 2014, a consensus conference took place where a large majority of the full task force was present. The explicit goal of this consensus conference was to establish guiding principles for working towards a definition of remission in SLE and to formulate proposed definitions that would be amenable to scientific testing. During this meeting, formal votes were taken on a range of points. The level for agreement was set at >90%.

The procedure was informed by the results of the systematic literature review that was carried out in the context of the ‘T2T/SLE’ project and was modified and updated in September 2015. We focused on 2 of the 12 original topics of interest that were more relevant to the present study, namely topic #2 (“Have any definitions for low disease activity and remission—both global and organ-specific—been validated as surrogates of therapeutic success against damage accrual, mortality and QoL in SLE?”) and topic #5 (“Is sustained reduction of disease activity or prevention of flares—both general and organ-specific—an achievable goal in SLE?”). The literature search was repeated in September 2015 by author GB to include more recently published literature. The PubMed database was searched using index terms and all English-language human studies were evaluated based on the title, abstract and/or full-text. For the purpose of the present study, we report on the systematic literature review results relevant to remission only, which were published since the year 1990 and included >70 patients with SLE.

**RESULTS**

Domains considered critical for defining remission in SLE

Four domains critical for defining remission in SLE were identified: clinical disease activity, serological activity, duration and treatment. Within each of these domains, a number of key issues were identified and these form the basis of the work described here.

**Preliminary statements on remission in SLE**

Ten statements, considered highly relevant for developing a definition of remission and expected to be uncontroversial, were prepared by the steering committee and subjected to electronic voting by the task force. Eight of these statements readily achieved a high level of consensus (>90%) and are shown in table 1.

<table>
<thead>
<tr>
<th>Statement</th>
<th>% in favour</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Remission is a desirable outcome for the patient with SLE.</td>
<td>100</td>
</tr>
<tr>
<td>2 Remission in SLE includes, at the very least, the absence of symptoms and signs of SLE.</td>
<td>100</td>
</tr>
<tr>
<td>3 Remission in SLE is not the same as a cure.</td>
<td>98</td>
</tr>
<tr>
<td>4 Remission in SLE is not the same as low disease activity.</td>
<td>93</td>
</tr>
<tr>
<td>5 Remission is a state that, if sustained, is associated with a low likelihood of adverse outcome.</td>
<td>100</td>
</tr>
<tr>
<td>6 ‘Serological activity’ in SLE generally refers to the presence of anti-DNA antibodies and/or hypocomplementemia.</td>
<td>100</td>
</tr>
<tr>
<td>7 Treatment with antimalarials does not preclude the patient from being considered to be in remission.</td>
<td>98</td>
</tr>
<tr>
<td>8 Treatment with moderate-dose or high-dose steroids does preclude the patient from being considered in remission.</td>
<td>98</td>
</tr>
</tbody>
</table>

Out of 10 statements selected by the steering committee, 8 achieved >90% agreement on electronic voting by the entire task force. Two statements ("A definition of remission SLE must be reasonably consistent with the use of this term in the literature" and "Durability in time can be added to any definition of remission in order to define a ‘durable remission’ but need not be included in the definition of remission itself") did not achieve consensus and were discussed further at the face-to-face meeting.

### Table 2  Validation of published definitions of disease remission against outcomes in SLE (studies with $n \geq 70$ patients)

<table>
<thead>
<tr>
<th>Author (ref.)</th>
<th>N</th>
<th>Remission definition(s)</th>
<th>Remission achieved (%)</th>
<th>Association of remission with outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General SLE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drenkard et al</td>
<td>667</td>
<td>$\geq 1$ year of clinically inactive disease (serological activity allowed) that permitted withdrawal of all lupus drugs</td>
<td>23.4%</td>
<td>12.5-fold reduced risk for death (follow-up 11.6–6.0 years), after controlling for effects of renal disease and thrombocytopenia</td>
</tr>
<tr>
<td>Nosent et al</td>
<td>200</td>
<td>Physician judgement (not otherwise specified), assessed during the first year of disease</td>
<td>27.5%</td>
<td>Lower annual relapse rates, lower average SLEDAI, lower cumulative SDI scores at the end of 5-year follow-up</td>
</tr>
<tr>
<td>Zen et al</td>
<td>224</td>
<td>$\geq 5$ years complete remission with SLEDAI-2K=0 (HCQ allowed) or clinical remission with clinical SLEDAI-2K=0 (serological activity allowed) off-steroids or on low-dose steroids (HCQ/NSAIDs allowed)</td>
<td>7.1% (complete remission), 14.7% (off-steroids), 15.6% (on steroids)</td>
<td>Damage accrual rates (end of 5-year follow-up): 18.8% (complete remission), 18.2% (off-steroids), 37.1% (on steroids) and 51.4% (no remission)</td>
</tr>
<tr>
<td>Medina-Quinones et al</td>
<td>532</td>
<td>$\geq 3$ years with BILAG C, D or E, no serological activity, off-steroids, off-immunosuppressives (HCQ/NSAIDs allowed)</td>
<td>14.5%</td>
<td>Lower mortality rates (5.2% vs 13.4%; median follow-up 12 years)</td>
</tr>
<tr>
<td><strong>Lupus nephritis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moroni et al</td>
<td>70</td>
<td>CRR: UP$^*$ &lt;0.2, normal renal function</td>
<td>38.5% (at last follow-up)</td>
<td>CRR was associated with fewer renal flares, better outcome of renal flares</td>
</tr>
<tr>
<td>Mok et al</td>
<td>183</td>
<td>CRR: UP &lt;0.3, normal SAlb, normal renal function, assessed at the end of first year of therapy</td>
<td>64%</td>
<td>Lack of CRR was associated (RR 9.9) with development of ESRD (mean follow-up 181 months)</td>
</tr>
<tr>
<td>Korbet et al</td>
<td>86</td>
<td>CRR: Scr $\leq 1.4$ mg/dL, UP $\leq 0.33$, attained within 5 years of entering the study: See also refs 13, 14</td>
<td>43%</td>
<td>CRR was associated with reduced risk of progression to ESRD (HR 0.12), increased rates of patient survival at 5 and 10 years (follow-up 120±65 months)</td>
</tr>
<tr>
<td>Illei et al</td>
<td>145</td>
<td>CRR: Scr $\leq 130$% of the lowest level during treatment, UP $&lt; 1$, inactive urinary sediment, off IST (HCQ and prednisone $\leq 10$ mg/day allowed), for $\geq 6$ months</td>
<td>50.3%</td>
<td>Lack of CRR was associated with increased risk for severe nephritic flare (likelihood ratio (LR) 5.7) and progression to ESRD (LR 7.0) (median follow-up 116 to 123 months)</td>
</tr>
<tr>
<td>Hill et al</td>
<td>71</td>
<td>CRR: Scr $&lt; 123$ μmol/L, UP $&lt;0.33$</td>
<td>NA/</td>
<td>Lack of CRR was associated with decreased 10-year survival rates from doubling of Scr</td>
</tr>
<tr>
<td>Mok et al</td>
<td>189</td>
<td>CRR: stabilised/improved Scr, UP &lt;1, improved serum C3 for $\geq 6$ months, assessed at the end of IST</td>
<td>55%</td>
<td>Lack of CRR was associated with increased risk (HR 4.5) for development of ESRD (mean follow-up 96.5 months)</td>
</tr>
<tr>
<td>Mok et al</td>
<td>268</td>
<td>Same as in 17</td>
<td>59%</td>
<td>Lack of CRR was associated with increased risk (HR 4.5) for adverse outcome (doubling of Scr or ESRD or patient death)</td>
</tr>
<tr>
<td>Moroni et al</td>
<td>93</td>
<td>CRR: Scr $&lt;1.2$ mg/dL, stable or 25% increase of baseline CrCl, UP &lt;0.2, inactive urinary sediment</td>
<td>82% (63.4% at last follow-up)</td>
<td>Lack of CRR was associated (RR 4.3) with development of chronic renal insufficiency (median follow-up 181 months)</td>
</tr>
<tr>
<td>Mak et al</td>
<td>149</td>
<td>CRR: stabilised/improved Scr, improved serum complement, UP &lt;1, inactive urinary sediment for $\geq 6$ months, assessed at the end of first year of therapy</td>
<td>60.4%</td>
<td>Lack of CRR was associated with renal damage (mean follow-up 80 months)</td>
</tr>
<tr>
<td>Lee et al</td>
<td>77</td>
<td>CRR: Scr $&lt;1.2$ mg/dL, UP &lt;0.2, inactive urinary sediment, for $\geq 6$ months</td>
<td>52%</td>
<td>Lack of CRR was associated with development of chronic renal insufficiency and/or death (follow-up 8.3±4.4 years)</td>
</tr>
<tr>
<td>Sun et al</td>
<td>100</td>
<td>CRR: UP &lt;0.4, normal urinary sediment, normal SAlb, normal Scr</td>
<td>58%</td>
<td>Lack of CRR was associated with ESRD (median follow-up 60 months)</td>
</tr>
<tr>
<td>Ayodele et al</td>
<td>105</td>
<td>CRR: stable ($\pm 25$%) renal function, UP &lt;0.2, assessed at the end of first year of therapy</td>
<td>44.8%</td>
<td>CRR was associated with higher mean survival time</td>
</tr>
<tr>
<td>So et al</td>
<td>117</td>
<td>CRR: Scr $\leq 1.4$ mg/dL, UP $&lt;0.5$, inactive urinary sediment, assessed after 6 months of therapy</td>
<td>50.4%</td>
<td>CRR was associated with reduced risk for subsequent renal flares and chronic renal failure (mean follow-up 66–76 months)</td>
</tr>
<tr>
<td>Reich et al</td>
<td>98</td>
<td>CRR: Scr $\leq 120$ mmol/L, (1.4 mg/dL), UP &lt;0.3</td>
<td>74.5%</td>
<td>Lack of CRR was associated with faster GFR decline (follow-up 12.4±8.4 years)</td>
</tr>
<tr>
<td>Alsuwaila et al</td>
<td>77</td>
<td>CRR: Scr $\leq 125$ μmol/L, UP &lt;0.33</td>
<td>41.6%</td>
<td>CRR was associated with higher renal survival rate at 10 years. Lower risk for doubling of Scr</td>
</tr>
<tr>
<td>Dhir et al</td>
<td>188</td>
<td>UP reduction by $\geq 50$% to &lt;2, inactive urinary sediment, normal Scr ($\leq 1.5$ mg/dL), assessed at the end of first year</td>
<td>54.6%†</td>
<td>Lack of remission was associated (HR 13.8) with chronic renal failure or death (median follow-up 6 years) and thrombocytopenia</td>
</tr>
<tr>
<td>Moroni et al</td>
<td>103</td>
<td>CRR: Scr $&lt;1.2$ mg/dL, stable or 25% increase of baseline CrCl, UP &lt;0.2, inactive urinary sediment</td>
<td>70.9%</td>
<td>CRR was associated with good renal outcome (no chronic renal insufficiency) (follow-up 156±105 months)</td>
</tr>
<tr>
<td>Mahmoud et al</td>
<td>135</td>
<td>CRR: Scr $&lt;1.2$ mg/dL, and 25% increase of baseline CrCl if abnormal, or stable value if abnormal at baseline, UP &lt;0.2, inactive urine sediment</td>
<td>59.3%</td>
<td>Lack of CRR in the first year was associated with adverse outcome (death, ESRD or doubling of Scr)</td>
</tr>
</tbody>
</table>

*Continued*
Table 2 Continued

<table>
<thead>
<tr>
<th>Author (ref.)</th>
<th>N</th>
<th>Remission definition(s)</th>
<th>Remission achieved (%)</th>
<th>Association of remission with outcomes</th>
</tr>
</thead>
</table>
| Fernandes das Neves et al
| 105 | CRR: UPr <0.2, negative anti-double stranded DNA antibodies, normal C3 and normal SCr, for ≥5 consecutive years | 38.1% | CRR was associated with preservation of normal renal function (80% vs 43%) and reduced mortality (0% vs 22%) compared with partial/no remission group (follow-up 13.7±14.1 years) |
| Koo et al | 193 | CRR: UPr <0.3, for ≥6 months | 42.5% | CRR was associated with reduced risk of mortality and ESRD (follow-up 158±70 months) |
| Dall’Era et al | 76 | Different sets of response criteria based on a range of cut-offs of UPr, Scr and RBCs at 3, 6 and 12 months. Best criterion was UPr <0.8 at 12 months | 59.2% | Sensitivity 81% and specificity 78% for favourable long-term (7 years) renal outcome (Scr ≤1.0 mg/dL). The LUNAR study remission criterion (UPr ≤0.5, Scr ≤15% of baseline, inactive urine sediment) had 32% sensitivity, 91% specificity |
| Tamirou et al | 104 | Different sets of CR criteria based on levels of UPr, Scr and urinary RBCs at 3, 6 and 12 months. Best criterion was UPr <0.5 at 12 months | 49.0% | Positive predictive value 92% for achieving good long-term renal outcome (Scr ≤120% of baseline value) after median 110 months |
| Tamirou et al
| 80 | Subgroup analysis of #3 Different sets of response criteria based on a range of cut-offs of UPr, Scr and RBCs at 3, 6 and 12 months. Best criterion was UPr <0.7 at 12 months | 63.8% | Sensitivity 71% and specificity 75% for favourable long-term (7 years) renal outcome (Scr ≤1.0 mg/dL) |

*UPr assessed by 24-hour urine collection and/or urine protein-to-creatinine ratio.

n=171 out of 130 with available records.

BILAG, British Isles Lupus Assessment Group; CRt, complete renal remission (or response); ESRD, end-stage renal disease; GFR, glomerular filtration rate; HCO3−, hydroxylchloroquine; IST, immunosuppressive treatment; LR, likelihood ratio; N/D, not described; NSAID, non-steroidal anti-inflammatory drug; RBCs, red blood cells; SAlb, serum albumin; SCr, serum creatinine; SLICC, Systemic Lupus International Collaborating Clinics; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; systemic lupus international collaborating clinics (SLICC) group damage index; UPr, proteinuria.

suggested to test each of the clinical criteria with and without serology, in order to determine the usefulness of the latter and whether it adds to the construct validity of each definition.

Finally, there was consensus in the task force that treatment with antimalarials does not preclude the patient from being considered to be in remission, even though it is somewhat paradoxical to say ‘off treatment’ when someone is, in fact, taking a medication. However, this step was strongly supported by the task force in respect of the widely held view that antimalarials are often considered long-term maintenance therapy for patients with SLE even if they have achieved remission. Benefits of such treatment are believed to extend beyond flare prevention and disease control, and it was therefore felt incorrect to imply that these medications should be discontinued. The task force does recognise that antimalarials have immunomodulatory effects, and that therefore studies done on patients in remission ‘off treatment’ (by the above definition) may in some instances have to distinguish clearly between those patients who are and who are not taking antimalarials. This would perhaps seem most important for studies of an immunological or pathophysiological nature. A similar argument does of course also apply to medications that do not fall in the above categories but that have or may have immunomodulatory properties, such as statins and vitamin D.

It was also agreed upon by all that patients who are treated with moderate-dose or high-dose glucocorticoids cannot be considered to be in remission, even if they would fulfil other criteria for remission. The main argument for this is the well-established adverse health consequence of long-term moderate-dose to high-dose glucocorticoid treatment.

Two statements were felt to be uncontroversial by the steering committee but did not achieve >90% agreement in the larger task force. One of these, “A definition of remission in SLE must be reasonably consistent with the use of this term in the literature” was intended by the steering committee as indicating that a definition of remission must be aligned with what historically has been considered to be a remission. However, this statement was felt to be a bit too circular by some, given that the literature is divided on the definition of remission.

The statement “Durability in time can be added to any definition of remission in order to define a ‘durable remission’—but need not be included in the definition of remission itself” achieved 86% agreement by premeeting electronic voting. Notably, although a few of the published definitions included in table 2 have incorporated a ‘duration’ component (ranging from 6 months to 5 years), the majority to the studies has not examined the prognostic importance of duration of remission against long-term patient outcomes. When discussed face-to-face by the full task force, an increasing number of delegates were unable to support this statement. After discussion, the vote was 65% in favour—not sufficient to declare consensus. The main arguments for and against this statement, as they were discussed during the meeting, are given in table 3.

The framework for a definition

The task force discussed what form a definition of remission in SLE should take. A literature search on this topic identified many observational studies and clinical trials that used a large number of different ad hoc definitions of remission in general SLE (see online supplementary appendix table S1) and in lupus nephritis (see online supplementary appendix table S2). After extensively reviewing various options, and with particular attention to the discussion described above regarding duration, the following three key principles were agreed upon (summarised in table 4):

1. The task force achieved consensus (93%) for the principle that remission in SLE will be defined using the following format:

   “Remission in SLE is a durable state characterized by …. (followed by a reference indicating the absence of symptoms, signs or abnormal labs)”.

   It can be recognised that this definition is to some extent a compromise because it does not specify the length of time during which a remission would have to be sustained in order to qualify. This is a direct result of the fact that no agreement on this could be achieved and that the task force felt that further scientific studies are needed to define the optimal duration for any statement of remission in SLE. A further area of uncertainty was whether the absence of
active serology would be required and yet again it was felt that this could be investigated in the future. It should therefore also be recognised that ‘abnormal labs’ in the above statement refers to routine laboratory assessments and not necessarily to anti-DNA antibodies or complement levels.

2. The task force spent much time on finding correct formulations for defining the absence of clinical signs and symptoms for use in a definition and agreed, in the end, that for this a validated index must be used (98% agreement). The task force specifically suggests that the following can be considered: clinical SLEDAI=0; BILAG 2004 D or E categories only or clinical ECLAM=0. Furthermore, it is recommended that each of these indices is supplemented with the requirement for the physician’s global assessment (PhGA) to be below a certain level: in the case of a PhGA ranging from 0 to 3 that should be <0.5. Note that in all instances the term ‘clinical’ for SLEDAI and ECLAM refers to symptoms, signs and routine laboratory testing and disregarding only the points that can be given for the presence of anti-DNA antibodies and/or low complement. The task force also discussed the possibility of defining remission in terms of specific symptoms and signs, such as was done for the proposed definition of remission in paediatric SLE, where certain symptoms and signs are ‘allowed’ for patients with SLE who are nevertheless considered to be in remission.38 Although a minority of participants favoured this approach, there was a more widespread feeling that not using validated indices would to some extent be retrograde, and that practice in various research settings would also increasingly be dominated by the use of such indices.

3. The task force recommends that a distinction should be made between ‘remission off therapy’ and ‘remission on therapy’ (100% agreement). These two descriptors were chosen in preference to many other suggested terms, some of which are: ‘complete’ versus ‘partial’ remission; ‘complete’ versus ‘clinical’ remission; ‘remission’ versus ‘lupus under control’ or ‘inactive disease’. While there are subtle nuances differentiating between these possibilities, it was considered important to simplify this matter and to strictly limit the number of definitions to two levels of remission.

In this regard, it is also important that ‘off therapy’ will mean that the patient is on no other immunomodulatory treatment for SLE than possibly antimalarials. As pointed out earlier, for some studies, in particular mechanistic investigations, the immunomodulatory properties of antimalarials must be considered, and in general accurate recording of all medications is recommended. ‘Remission on therapy’ will allow some, but not all medications. Specifically, stable immunosuppressives, including biological immunomodulators, are allowed within this level of remission. It was noted that definitions of remission in other autoimmune diseases, including rheumatoid arthritis35 and Crohn’s disease,36 do not exclude the chronic use of specific antirheumatic medications, immunosuppressives or biologics. Likewise, these definitions do not limit the use of glucocorticoids. However, in SLE a major contributor to long-term damage and other adverse outcomes is the chronic use of glucocorticoids, and the task force felt that for the patient to be declared in ‘remission on treatment’ the highest allowable dose of glucocorticoids is 5 mg/day prednisone (or equivalent). Prednisone dose thresholds associated with protection from treatment-related harm are currently being studied by several groups and data from those studies should further inform the selection of a threshold glucocorticoid dose in a definition of remission on therapy.

Further development of the most appropriate definition of remission
The task force discussed in what manner a future definition of remission in SLE could be most thoroughly established.
It was agreed upon by voting that for testing the construct validity of each potential remission definition the most

---

**Table 4** The task force’s three key recommendations for defining remission in SLE

<table>
<thead>
<tr>
<th>Key principles for defining remission in SLE</th>
<th>Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Definitions of remission in SLE will be worded as follows: Remission in SLE is a durable state characterized by …………………. (reference to symptoms, signs, routine lab)</td>
<td>93% (2 abstained)</td>
</tr>
<tr>
<td>Requirement for serology may be added</td>
<td></td>
</tr>
<tr>
<td>2. For defining remission in SLE, a validated index must be used</td>
<td>98%</td>
</tr>
<tr>
<td>– Suggested indices are: clinical SLEDAI=0; BILAG 2004 D or E only; clinical ECLAM=0</td>
<td></td>
</tr>
<tr>
<td>– These must be supplemented by the physician’s global assessment being below an appropriate threshold (eg. &lt;0.5 on a 0–3 scale)</td>
<td></td>
</tr>
<tr>
<td>3. A distinction will be made between remission off therapy and remission on therapy</td>
<td>100% (3 abstained)</td>
</tr>
<tr>
<td>– Remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials</td>
<td></td>
</tr>
<tr>
<td>– Remission on therapy allows patients to be treated with maintenance antimalarials, stable, low-dose glucocorticoids (eg. prednisone ≤5 mg/day), maintenance immunosuppressives and/or stable (maintenance) biologics</td>
<td></td>
</tr>
</tbody>
</table>

ECLAM, European consensus lupus outcome measure; SLE, systemic lupus erythematosus.
appropriate outcomes are death, damage, lupus flares and HR-QOL measures (100% agreement).

Thus, the task force indicated that any definition of remission in SLE must be tested in terms of the degree to which it correctly identifies patients whose future disease course will be better in these four outcomes. Although mortality remains a key outcome, it is unlikely that many studies will be able to identify this as a differentiating factor. Damage as measured by the systemic lupus international collaborating clinics (SLICC) damage index will most likely be the most effective way of ascertaining the construct validity of a definition of remission, as has been provisionally demonstrated for the definition of LLDAS. However, the occurrence of flares, especially severe flares, that can be measured by a variety of instruments, and measures of HR-QoL will also be important in determining which potential definition of remission in SLE has the greatest validity.

Other points of discussion
Patient’s global assessment
There was controversy about the role of the patient’s global assessment (PGA) in a remission definition. A majority felt that PGA cannot currently be included pending further research, and specifically that such research is needed to validate PGA as an outcome in reference to remission. Many felt that a better instrument to capture the patient’s perspective may be needed. However, patient representatives (authors KL, CC and BvL) were concerned that the patient’s perspective was omitted. Indeed, in the T2T recommendations for SLE, both overarching principles and specific recommendations advocate including the patient’s perspective in decision-making. However, there is no fully validated measure for the patient’s perspective at this time. It was remarked that the PhGA can reflect patient’s perspective, and it was proposed to emphasise that PhGA should pay careful attention to patient symptoms, or conversely, that PGA could be a long-term outcome used in the testing of remission definitions; but in formal votes no consensus was reached on these points.

Inclusion of validated skin score
The dermatologists in the task force (authors AK and VPW) suggested to supplement the definition of remission with a validated skin score.

Definition based only on symptoms
A rheumatologist (author MW) pointed out that in as much as the task force is developing possible definitions of remission, a definition based only on symptoms and without the use of an index could also be tested.

Plans for further work and research agenda
The task force agreed upon a plan of work that would include the use of longitudinal datasets from clinical trials, observational studies, registries, etc to test each of the definitions of remission. Likewise, definitions of remission ‘on treatment’ and ‘off treatment’ will be tested separately against the prespecified dependent outcomes indicated above, and different durations of these definitions will also be tested. Moreover, studies done on patients ‘off treatment’ will also record the use of antimalarials and analyse the extent to which this makes a difference. As always, findings in such subanalyses may inform future changes in the proposed definitions.

Proposed durations to be analysed include 6 months, 12 months, 2 years and 5 years.

In addition to this continued work, the task force also recommends specific research to investigate whether definitions of remission are applicable irrespective of genetic backgrounds and/or ethnicity.

DISCUSSION
An international task force consisting of patient representatives and specialists in clinical immunology, dermatology, nephrology and rheumatology was convened and achieved high-level agreement on eight statements, three key principles and a set of outcomes relating to remission in SLE, thereby providing a road map for further work towards a generally applicable definition.

Remission was approached as a global state, whereas it is recognised that remission can be defined, and has in some instances been defined, at the individual organ system level.

As a conceptual starting-point remission was identified as a desirable outcome for patients with SLE with at the very least the absence of major symptoms and signs of SLE. Remission is considered distinct from a cure and it is also regarded as meaningfully different from a state of low disease activity in SLE such as the LL/DAS that has recently been developed by the Asia-Pacific Lupus Collaboration. However, the latter definition does not solely require the presence of low disease activity and does therefore, in fact, include both patients who have a low level of disease activity and also those who are in remission.

Perhaps most critically for future work in this area, it is recognised that remission has to be a state that, if sustained, is associated with a low likelihood of adverse outcome.

Regarding treatment, there was consensus that treatment with antimalarials does not preclude the patient from being considered to be in remission, in respect of the recommendation that antimalarials should be considered as long-term maintenance therapy for patients with SLE even if they have achieved remission. It was also agreed upon by all that patients who are treated with moderate-dose or high-dose glucocorticoids cannot be considered to be in remission even if they would fulfil other criteria for remission. It is well established that glucocorticoids may suppress signs of disease, but will not achieve bona fide disease control, and also constitute one of the major risk factors for negative outcomes in SLE.

In contrast to these areas of agreement, no consensus could be achieved on two important issues.

First, it transpired that the inclusion of ‘duration’ in a definition of remission was controversial. Some argued that definitions of remission in other disease areas do not have this requirement, and that utility of a definition in clinical studies including clinical trials will be significantly limited if duration is explicitly required. Others argued that remission achieved on only one given point in time lacks clinical relevance in a disease that can be relapsing and remitting. Following lengthy discussion, the task force was able to agree on a compromise using the wording “Remission is a durable state characterised by….” and also clearly identified the need for studies linking the duration of any definition of remission with long-term outcomes.

Second, the task force did not agree on the precise role of the PGA in a remission definition. This issue was debated at considerable length. Several task force members including patient representatives were concerned that the patient’s perspective was not explicitly included in the definition, and emphasised the importance of a definition of remission that ‘resonates’ with the patient. However, a majority of the task force felt that while the patient’s perspective is critically important in the patient-physician interaction, when it comes to a definition of remission for the purposes of clinical and epidemiological studies and...
Clinical and epidemiological research

clinical trials, more work is needed in order to either validate PGA as an outcome or more likely to develop a better instrument to capture the patient’s perspective. It was pointed out that the physician, when assessing disease activity, is expected to weigh in the patient’s perspective.

Additionally, the task force agreed on the definition of ‘serological activity,’ but no consensus was reached regarding whether the latter should be taken into account to define remission. The task force agreed upon the use of longitudinal datasets to determine whether serology adds to the construct validity of each definition.

Nomenclature for remission in SLE was extensively discussed. Many terms were proposed, including ‘complete remission,’ ‘partial remission,’ ‘clinical remission,’ ‘serological remission,’ ‘lupus under control,’ ‘inactive disease,’ etc, many of which were overlapping. In order to simplify matters and achieve consistency, the task force recommends that only one distinction is made between ‘remission off therapy’ and ‘remission on therapy,’ where ‘off therapy’ must mean that the patient is on no systemic treatments for SLE other than antimalarials. While ‘remission on antimalarials only’ would be the most accurate term for this state, remission off therapy was chosen for brevity and convenience, even though it does allow antimalarial therapy. As stated previously, it will be necessary in future studies to account for the actual use of antimalarials in this group of patients, and subsequent analyses of patients who are and who are not on antimalarials may lead to further distinctions in these categories.

‘Remission on therapy’ will allow stable immunosuppressives, including biologics, and low-dose glucocorticoids. It is of interest to note that the latter type of definition is the more usual in other autoimmune diseases, such as rheumatoid arthritis and Crohn’s disease, and would also allow investigators to use the definition in clinical trials.

One limitation of the approach taken by the task force is the decision to limit serological activity to anti-DNA antibodies and low complement. Recent research shows the importance of antibodies to RNA binding proteins to the formation of immune complexes that can stimulate interferon production. Further research may show that, unless these antibodies are assayed, the serological assessment is incomplete.

Finally, the task force recommends a clear research agenda of testing the construct validity of potential remission definitions against death, damage, lupus flares and HR-QOL measures as outcomes (dependent variables) in suitable cohorts of patients. Several task force members have conducted or are conducting such studies. This approach will establish which definition(s) of remission in SLE optimally identifies patients with a better disease course in these four outcomes.

In summary, a set of statements and key principles relevant to remission in SLE were established by an international task force. This work provides a pathway for testing individual definitions against long-term outcomes in order to arrive at a definition of remission in SLE.

Author affiliations

1Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Karolinska Institutet, D1:00 Karolinska University Hospital, Solna, Stockholm, Sweden

2Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands

3Department of Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Iraklion, Greece

4Feinstein Institute for Medical Research, Manhasset, New York, USA

5Department of Medicine III, University Medical Center TU Dresden, Dresden, Germany

6New York University, New York, USA

7LRe SR—Klub Motýlik, Bratislava, Slovakia

8Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

9Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

10Department of Medicine and Joint Academic Rheumatology Program Medical School, National and Kapodestrian University of Athens, Athens, Greece

11NIHR Manchester Biomedical Research Unit, The University of Manchester and Central Manchester Foundation Trust, Manchester, UK

12Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain

13Division of Rheumatology, The Arthritis Society Chair in Rheumatic Diseases Cumming School of Medicine University of Calgary, Calgary, Alberta, Canada

14Lupus Foundation of America, Washington DC, USA

15Université Paris-Descartes, Paris, France

16AP-HP, Hôpital Cochin, service de médecine interne, centre de reference maladies auto-immunes et systémiques rares, Paris, France

17Department of Rheumatology and Immunology, Institute of Bioanalysis, Institute of Family Medicine, University of Oulu, Finland

18Third Department of Internal Medicine, Semmelweis University, Budapest, Hungary

19Department Rheumatology and Clinical Immunology, University Medical Center, Utrecht, The Netherlands

20Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy

21Department Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany

22Polyclinic of Rheumatology, Hiller Research Unit, University Clinic Dusseldorf, Heinrich-Heine-University, Dusseldorf, Germany

23Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

24Division of Rheumatology, Medical University of Graz, Graz, Austria

25Service de Rhumatologie, Cliniques universitaires Saint-Luc, Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Experimtale et Clinique, Université catholique de Louvain, Bruxelles, Belgium

26Department of Medicine, The Centre for Rheumatology, University College London, UK

27Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark

28Department of Medicine, University of Cambridge, Cambridge, UK

29Interdisciplinary Center for Clinical Trials (IZKS), University Medical Center Mainz, Mainz, Germany

30LUPUS EUROPE, co-opted trustee for research, Essex UK

31Rheumatology Department, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

32Université Paris-Sud; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-sud; INSERM U1184, Le Kremlin Bicêtre, France

33Bone Densitometry Unit, Monta Hospital, Tripoli, Lebanon

34Monash University, Faculty of Medicine, Nursing & Health Sciences, Monash Medical Centre, Clayton, Australia

35Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

36Department of Internal Medicine, Division of Rheumatology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

37University of Santo Tomas, Manila, Philippines

38Vasculitis.at, Vienna, Austria

39Department of Connective Tissues Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation of NY, Pecs, Hungary

40Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

41RNA and Molecular Pathology Research Group, Institute of Medical Biology, Health Science Faculty, University of Tromsø, Tromsø, Norway

42National Institute for Rheumatic Diseases, Piestany, Slovak Republic

43Zabrdettes Center for Autoimmune Diseases, Sheba Medical Center (Affiliated to Tel-Aviv University), Tel-Aviv, Israel

44Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria

452nd Department of Medicine, Hietzing Hospital, Vienna, Austria

46Diaprtimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, U.O. Reumatologia e Immunologia Clinica, Spedali Civili di Brescia, Brescia, Italy

47Centre for Prognosis Studies in the Rheumatic Diseases, Senior Scientist Krembil Research Institute, Professor Medicine, University of Toronto, Toronto Western Hospital EW 1-409, Toronto, Canada

48Unidade de Imunologia Clinica, Hospital Santo Antônio, Centro Hospitalar do Porto, UMIB, Instituto de Ciencias Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal

49Department of Rheumatology, Odense University Hospital, University of Southern Denmark, Denmark

50Corpsal Michael J. Crescenz VA Medical Center (Philadelphia), Philadelphia, Philadelphia, USA


Acknowledgements The authors wish to acknowledge Ms Lisbeth Løfstrand, Administrator at Karolinska Institutet for her invaluable help during the organisation of the DORIS meetings as well as for manuscript preparation.

Competing interests RV reports having received Research Support and Grants for manuscript preparation. Administrator at Karolinska Institutet for her invaluable help during the organisation of the DORIS meetings as well as for manuscript preparation.

The authors wish to acknowledge Ms Lisbeth Löfstrand, Administrator at Karolinska Institutet for her invaluable help during the organisation of the DORIS meetings as well as for manuscript preparation.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


